应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01801 信达生物
已收盘 07-22 16:08:56
42.200
+1.650
+4.07%
最高
42.450
最低
40.550
成交量
704.25万
今开
40.600
昨收
40.550
日振幅
4.69%
总市值
687.19亿
流通市值
687.19亿
总股本
16.28亿
成交额
2.95亿
换手率
0.43%
流通股本
16.28亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
信达生物现涨超4% 宣布玛仕度肽糖尿病III期DREAMS-1研究成功
新浪港股 · 10:35
信达生物现涨超4% 宣布玛仕度肽糖尿病III期DREAMS-1研究成功
港股异动 | 信达生物(01801)涨近3% 宣布玛仕度肽糖尿病III期DREAMS-1研究成功
智通财经 · 10:30
港股异动 | 信达生物(01801)涨近3% 宣布玛仕度肽糖尿病III期DREAMS-1研究成功
信达生物(01801)出现大手成交110万股,成交价$41.725,涉资4.59千万
阿斯达克财经 · 10:30
信达生物(01801)出现大手成交110万股,成交价$41.725,涉资4.59千万
信达生物宣布玛仕度肽糖尿病III期DREAMS-1研究成功,将于近期递交上市申请
美通社 · 08:00
信达生物宣布玛仕度肽糖尿病III期DREAMS-1研究成功,将于近期递交上市申请
信达生物(01801)出现大手卖出25.4万股,成交价$41.75,涉资1.06千万
阿斯达克财经 · 07-17
信达生物(01801)出现大手卖出25.4万股,成交价$41.75,涉资1.06千万
港股异动 | 信达生物(01801)午后涨超4% 野村上调信迪利单抗销售额预测 预计公司明年扭亏
智通财经 · 07-17
港股异动 | 信达生物(01801)午后涨超4% 野村上调信迪利单抗销售额预测 预计公司明年扭亏
信达生物(01801)上涨4.39%,报41.6元/股
金融界 · 07-17
信达生物(01801)上涨4.39%,报41.6元/股
信达生物07月16日获主力加仓1218万元 环比增加836.92%
自选股智能写手 · 07-16
信达生物07月16日获主力加仓1218万元 环比增加836.92%
信达生物(01801)出现大手卖出50万股,成交价$39.2,涉资1.96千万
阿斯达克财经 · 07-16
信达生物(01801)出现大手卖出50万股,成交价$39.2,涉资1.96千万
野村:维持信达生物(01801)“买入”评级 目标价升至55.87港元
智通财经网 · 07-16
野村:维持信达生物(01801)“买入”评级 目标价升至55.87港元
The Capital Group Companies, Inc.减持信达生物(01801)275.5万股 每股作价约为36.09港元
智通财经 · 07-15
The Capital Group Companies, Inc.减持信达生物(01801)275.5万股 每股作价约为36.09港元
信达生物(01801)出现大手买入15.3万股,成交价$39.375,涉资602.438万
阿斯达克财经 · 07-15
信达生物(01801)出现大手买入15.3万股,成交价$39.375,涉资602.438万
信达生物盘中异动 早盘股价大涨5.08%报40.300港元
自选股智能写手 · 07-12
信达生物盘中异动 早盘股价大涨5.08%报40.300港元
信达生物07月11日获主力加仓2967万元 环比增加1178.88%
自选股智能写手 · 07-11
信达生物07月11日获主力加仓2967万元 环比增加1178.88%
【港股通】信达生物(01801)回升近5% 近日入股驯鹿生物 成为其战略股东
金吾财讯 · 07-11
【港股通】信达生物(01801)回升近5% 近日入股驯鹿生物 成为其战略股东
信达生物(01801)上涨5.12%,报37.95元/股
金融界 · 07-11
信达生物(01801)上涨5.12%,报37.95元/股
信达生物盘中异动 大幅拉升5.12%
自选股智能写手 · 07-11
信达生物盘中异动 大幅拉升5.12%
信达生物现涨超4% 圣因生物与信达生物共同开发的小核酸药物获批临床
新浪港股 · 07-11
信达生物现涨超4% 圣因生物与信达生物共同开发的小核酸药物获批临床
港股异动 | 信达生物(01801)涨超4% 圣因生物与信达生物共同开发的小核酸药物获批临床
智通财经 · 07-11
港股异动 | 信达生物(01801)涨超4% 圣因生物与信达生物共同开发的小核酸药物获批临床
大行评级|中银国际:信达生物近期披露差异化资产的积极数据 上调目标价至56港元
格隆汇资讯 · 07-09
大行评级|中银国际:信达生物近期披露差异化资产的积极数据 上调目标价至56港元
暂无数据
公司概况
公司名称:
信达生物
所属市场:
SEHK
上市日期:
--
主营业务:
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
发行价格:
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":42.2,"timestamp":1721635736028,"preClose":40.55,"halted":0,"volume":7042472,"delay":0,"floatShares":1628413570,"shares":1628413570,"eps":-0.70565355,"marketStatus":"已收盘","marketStatusCode":5,"change":1.65,"latestTime":"07-22 16:08:56","open":40.6,"high":42.45,"low":40.55,"amount":295317782,"amplitude":0.046856,"askPrice":42.25,"askSize":1000,"bidPrice":42.2,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":-0.7066481894976813,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":1540915200000,"adjPreClose":40.55,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":1.303214,"impliedVol":0.5566,"impliedVolPercentile":0.4453,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801/tweets","defaultTab":"tweets","newsList":[{"id":"2453789325","title":"信达生物现涨超4% 宣布玛仕度肽糖尿病III期DREAMS-1研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789325","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453789325?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:35","pubTimestamp":1721615727,"startTime":"0","endTime":"0","summary":"信达生物(01801)早盘涨幅持续扩大,股价上涨4.07%,现报42.20港元,成交额1.19亿港元。\n 今日信达生物宣布,胰高血糖素样肽-1受体(GLP-1R)/胰高血糖素受体(GCGR)双重激动剂玛仕度肽(研发代号:IBI362)在中国2型糖尿病受试者中开展的III期临床研究(DREAMS-1)达成首要终点和全部关键次要终点,展现出降糖、减重双达标及心血管肾脏代谢指标的综合获益。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-22/doc-inceypai1516655.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-22/doc-inceypai1516655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["LU1969619763.USD","BK1589","LU2328871848.SGD","BK1583","01801","BK1161"],"gpt_icon":0},{"id":"2453864797","title":"港股异动 | 信达生物(01801)涨近3% 宣布玛仕度肽糖尿病III期DREAMS-1研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2453864797","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453864797?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:30","pubTimestamp":1721615412,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物(01801)涨近3%,截至发稿,涨2.84%,报41.65港元,成交额5271.76万港元。消息面上,今日信达生物宣布,胰高血糖素样肽-1受体(GLP-1R)/胰高血糖素受体(GCGR)双重激动剂玛仕度肽(研发代号:IBI362)在中国2型糖尿病受试者中开展的III期临床研究(DREAMS-1)达成首要终点和全部关键次要终点,展现出降糖、减重双达标及心血管肾脏代谢指标的综合获益。此外,信达生物计划于近期向国家药品监督管理局(NMPA)药品审评中心(CDE)递交玛仕度肽治疗2型糖尿病的新药上市申请(NDA),其首个减重适应症已于2024年初获受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2328871848.SGD","BK4134","LU1969619763.USD","BK1583","01801","HSTECH","YANG","HSCEI","III","BK1589"],"gpt_icon":1},{"id":"2453620789","title":"信达生物(01801)出现大手成交110万股,成交价$41.725,涉资4.59千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2453620789","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453620789?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:30","pubTimestamp":1721615400,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在上午10:30出现大手成交,成交量为110万,成交价为港币$41.725,涉资4.59千万。至目前为止,股价升2.836%,今日最高价为$41.8,而最低价为$40.55,总成交量为250.7万股,总成交金额港币$1.041亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407223618/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1969619763.USD","BK1583","LU2328871848.SGD","BK1589","BK1161","01801"],"gpt_icon":0},{"id":"2453046622","title":"信达生物宣布玛仕度肽糖尿病III期DREAMS-1研究成功,将于近期递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2453046622","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453046622?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:00","pubTimestamp":1721606400,"startTime":"0","endTime":"0","summary":"此前玛仕度肽头对头度拉糖肽治疗2型糖尿病的III期临床DREAMS-2也已达成研究终点,玛仕度肽展现出显著优效于度拉糖肽的降糖疗效,并在减重、心血管代谢指标均展示出了更优越的综合获益。玛仕度肽组的HbA1c降幅疗效维持至第48周。玛仕度肽另一项糖尿病III期研究DREAMS-2的研究结果已于2024年5月达成研究终点。2024年2月,玛仕度肽的首个NDA获NMPA受理,用于成人肥胖或超重患者的长期体重控制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4466060_ZH66060_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1969619763.USD","BK4134","BK1589","BK1583","BK4139","IVBIY","BK1161","01801","LU2328871848.SGD","III"],"gpt_icon":0},{"id":"2452900394","title":"信达生物(01801)出现大手卖出25.4万股,成交价$41.75,涉资1.06千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2452900394","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452900394?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:54","pubTimestamp":1721195640,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在下午01:54出现大手卖出,成交量为25.4万,成交价为港币$41.75,涉资1.06千万。至目前为止,股价升4.893%,今日最高价为$41.8,而最低价为$40.0,总成交量为855.418万股,总成交金额港币$3.514亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407173924/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","BK1161","BK1589","LU1969619763.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2452990783","title":"港股异动 | 信达生物(01801)午后涨超4% 野村上调信迪利单抗销售额预测 预计公司明年扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2452990783","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452990783?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:47","pubTimestamp":1721195263,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物午后涨超4%,截至发稿,涨4.52%,报41.65港元,成交额3.21亿港元。野村发表研究报告,将信达生物核心产品肺癌新药PD-1抗体信迪利单抗Tyvyt今明两年销售额预测,从29亿及30亿元人民币,上调至32亿及34亿元人民币,并相应将今年净亏损预测收窄至5.11亿元人民币,预期公司将于2025年扭亏,明年净利润预测上调12%至2.02亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","BK1583","LU1969619763.USD","HSCEI","BK1589","YANG","BK1161","LU2328871848.SGD","HSTECH"],"gpt_icon":1},{"id":"2452558907","title":"信达生物(01801)上涨4.39%,报41.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452558907","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452558907?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:36","pubTimestamp":1721194600,"startTime":"0","endTime":"0","summary":"7月17日,信达生物(01801)盘中上涨4.39%,截至13:36,报41.6元/股,成交3.0亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物,已成功上市10个产品,同时有4个品种在审评中,4个新药分子进入III期或关键性临床研究,另有18个新药品种已入临床研究。至2023年10月,其患者援助项目已惠及17余万患者,药物捐赠总价值达34亿人民币。截至2023年年报,信达生物营业总收入62.06亿元、净利润-10.28亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/17133641615657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2328871848.SGD","BK1583","BK1589","LU1969619763.USD","BK1161","01801"],"gpt_icon":0},{"id":"2451950655","title":"信达生物07月16日获主力加仓1218万元 环比增加836.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451950655","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451950655?lang=zh_cn&edition=full","pubTime":"2024-07-16 16:15","pubTimestamp":1721117748,"startTime":"0","endTime":"0","summary":"07月16日, 信达生物股价涨1.92%,报收39.85元,成交金额1.57亿元,换手率0.24%,振幅2.43%,量比0.60。信达生物今日主力资金净流入1218万元,连续5日净流入,上一交易日主力净流入130万元,今日环比增加836.92%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为42.86%,平均涨幅为3.36%。该股近5个交易日上涨9.02%,主力资金累计净流入1.07亿元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入1.67亿元,其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071616161795c61eaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071616161795c61eaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1589","LU1969619763.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2451793260","title":"信达生物(01801)出现大手卖出50万股,成交价$39.2,涉资1.96千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2451793260","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451793260?lang=zh_cn&edition=full","pubTime":"2024-07-16 13:10","pubTimestamp":1721106600,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在下午01:10出现大手卖出,成交量为50万,成交价为港币$39.2,涉资1.96千万。至目前为止,股价升0.512%,今日最高价为$39.9,而最低价为$39.05,总成交量为201.671万股,总成交金额港币$7.945千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407163661/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","LU1969619763.USD","BK1583","LU2328871848.SGD","01801","BK1589"],"gpt_icon":0},{"id":"2451987684","title":"野村:维持信达生物(01801)“买入”评级 目标价升至55.87港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451987684","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451987684?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:21","pubTimestamp":1721096475,"startTime":"0","endTime":"0","summary":"野村将信达生物(01801)核心产品肺癌新药PD-1抗体信迪利单抗Tyvyt今明两年销售额预测上调至32亿及34亿元人民币。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240716/20240716102226_27725.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240716/20240716102226_27725.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01801"],"gpt_icon":0},{"id":"2451617508","title":"The Capital Group Companies, Inc.减持信达生物(01801)275.5万股 每股作价约为36.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451617508","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451617508?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:56","pubTimestamp":1721037390,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新数据显示,7月10日,The Capital Group Companies, Inc.减持信达生物(01801)275.5万股,每股作价约为36.0878港元,总金额约9942.8万港元。减持后最新持股数目约为1.13亿万股,持股比例为6.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151828079f4e5d4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151828079f4e5d4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","01801","BK1161","BK1583","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2451649096","title":"信达生物(01801)出现大手买入15.3万股,成交价$39.375,涉资602.438万","url":"https://stock-news.laohu8.com/highlight/detail?id=2451649096","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451649096?lang=zh_cn&edition=full","pubTime":"2024-07-15 11:33","pubTimestamp":1721014380,"startTime":"0","endTime":"0","summary":"[大手成交]信达生物(01801)在上午11:33出现大手买入,成交量为15.3万,成交价为港币$39.375,涉资602.438万。至目前为止,股价跌3.44%,今日最高价为$41.0,而最低价为$39.25,总成交量为201.56万股,总成交金额港币$8.024千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407153343/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","LU1969619763.USD","BK1583","LU2328871848.SGD","01801","BK1589"],"gpt_icon":0},{"id":"2450342815","title":"信达生物盘中异动 早盘股价大涨5.08%报40.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450342815","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450342815?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:42","pubTimestamp":1720748544,"startTime":"0","endTime":"0","summary":"2024年07月12日早盘09时42分,信达生物股票出现异动,股价大幅拉升5.08%。截至发稿,该股报40.300港元/股,成交量220.694万股,换手率0.14%,振幅3.39%。信达生物股票所在的药品行业中,整体涨幅为0.08%。其相关个股中,和黄医药、信达生物、长江生命科技涨幅较大,振幅较大的相关个股有顺腾国际控股、开拓药业-B、和黄医药,振幅分别为14.63%、7.77%、5.23%。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712094224aef953d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712094224aef953d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","01801","LU1969619763.USD","BK1589","BK1161","BK1583"],"gpt_icon":0},{"id":"2450533849","title":"信达生物07月11日获主力加仓2967万元 环比增加1178.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450533849","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450533849?lang=zh_cn&edition=full","pubTime":"2024-07-11 16:15","pubTimestamp":1720685759,"startTime":"0","endTime":"0","summary":"07月11日, 信达生物股价涨6.23%,报收38.35元,成交金额2.71亿元,换手率0.44%,振幅6.51%,量比1.19。信达生物今日主力资金净流入2967万元,上一交易日主力净流入232万元,今日环比增加1178.88%。该股近5个交易日上涨2.97%,主力资金累计净流入4476万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入1.10亿元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071116161995a4c8f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071116161995a4c8f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1583","BK1589","LU1969619763.USD","BK1161","01801"],"gpt_icon":0},{"id":"2450780569","title":"【港股通】信达生物(01801)回升近5% 近日入股驯鹿生物 成为其战略股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2450780569","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450780569?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:16","pubTimestamp":1720667790,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物 股价反弹回升,截至发稿,报37.85刚玉按,涨4.85%,成交额1.2亿港元。同时信达生物将按照相同价格入股驯鹿生物,入股后将持有驯鹿生物的18%权益,成为战略股东。该行维持信达生物“买入”评级,并根据近期研发管线进展,将目标价上调至56港元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/YTRkZDA5YTgxZWQ0MTEwZDc5YTAxMjcyMzM1OTMwMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YTRkZDA5YTgxZWQ0MTEwZDc5YTAxMjcyMzM1OTMwMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940197","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","BK1583","HSCEI","YANG","BK1161","BK1589","LU1969619763.USD","01801","LU2328871848.SGD","HSTECH"],"gpt_icon":0},{"id":"2450870174","title":"信达生物(01801)上涨5.12%,报37.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450870174","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450870174?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:32","pubTimestamp":1720665155,"startTime":"0","endTime":"0","summary":"7月11日,信达生物(01801)盘中上涨5.12%,截至10:32,报37.95元/股,成交9625.16万元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物,已成功上市10个产品,同时有4个品种在审评中,4个新药分子进入III期或关键性临床研究,另有18个新药品种已入临床研究。至2023年10月,其患者援助项目已惠及17余万患者,药物捐赠总价值达34亿人民币。截至2023年年报,信达生物营业总收入62.06亿元、净利润-10.28亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/11103241505400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2328871848.SGD","BK1589","BK1583","LU1969619763.USD","BK1161","01801"],"gpt_icon":0},{"id":"2450704138","title":"信达生物盘中异动 大幅拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450704138","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450704138?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:32","pubTimestamp":1720665138,"startTime":"0","endTime":"0","summary":"2024年07月11日早盘10时32分,信达生物股票出现异动,股价急速上涨5.12%。信达生物股票所在的药品行业中,整体涨幅为0.35%。驯鹿生物7月5日披露称,公司将按照约定价格购买信达生物在原BCMA CAR-T合作协议项下拥有的相关权益;同时,信达生物将按照相同价格入股驯鹿生物,入股后将持有驯鹿生物18%的股份比例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711103219941f6213&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711103219941f6213&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1589","LU1969619763.USD","01801","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2450531870","title":"信达生物现涨超4% 圣因生物与信达生物共同开发的小核酸药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2450531870","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450531870?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:30","pubTimestamp":1720665050,"startTime":"0","endTime":"0","summary":"信达生物(01801)早盘持续走高,股价上涨4.57%,现报37.75港元,成交额9122.97万港元。\n 7月9日,北极光投资企业苏州圣因生物医药有限公司宣布,与信达生物制药集团共同开发的用于治疗高血压的小核酸(siRNA)药物SGB-3908注射液临床试验申请已获得国家药品监督管理局药品审评中心(CDE)临床试验申请默示许可(受理号:CXHL2400426),用于治疗高血压。这是圣因生物继SGB-3403注射液、SGB-9768注射液之后在国内申请开展临床试验的第三款siRNA药物。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-11/doc-incctqvf1952537.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-11/doc-incctqvf1952537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1583","BK1161","BK1589","LU1969619763.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2450773008","title":"港股异动 | 信达生物(01801)涨超4% 圣因生物与信达生物共同开发的小核酸药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2450773008","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450773008?lang=zh_cn&edition=full","pubTime":"2024-07-11 10:11","pubTimestamp":1720663909,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物涨超4%,截至发稿,涨4.43%,报37.70港元,成交额7498.36万港元。消息面上,7月9日,北极光投资企业苏州圣因生物医药有限公司宣布,与信达生物制药集团共同开发的用于治疗高血压的小核酸药物SGB-3908注射液临床试验申请已获得国家药品监督管理局药品审评中心临床试验申请默示许可,用于治疗高血压。这是圣因生物继SGB-3403注射液、SGB-9768注射液之后在国内申请开展临床试验的第三款siRNA药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1589","07226","HSTECH","LU1969619763.USD","01801","LU2328871848.SGD","YANG","HSCEI","BK1583"],"gpt_icon":0},{"id":"2450013094","title":"大行评级|中银国际:信达生物近期披露差异化资产的积极数据 上调目标价至56港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450013094","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450013094?lang=zh_cn&edition=full","pubTime":"2024-07-09 17:09","pubTimestamp":1720516169,"startTime":"0","endTime":"0","summary":"中银国际发表报告指,信达生物最近披露差异化资产的积极数据,包括玛仕度肽的GLORY-1三期研究结果以及IBI343和IBI363等潜在同类首创新分子类型资产的初步数据。报告指,信达生物已上市的产品组合,比如PD-1,VEGF,PCSK9,TNF-α,分别针对肿瘤、心血管及代谢,以及自身免疫领域的大量患者群体,信达有望利用这些治疗领域内的协同效应,将新产品组合更好更快的推向市场。该行维持信达生物“买入”评级,并根据近期研发管线进展,将目标价上调至56港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240709171036959625d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0629},{"period":"3month","weight":0.2214},{"period":"6month","weight":0.1202},{"period":"1year","weight":0.2976},{"period":"ytd","weight":-0.0515}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.021556},{"month":8,"riseRate":0.8,"avgChangeRate":-0.016733},{"month":9,"riseRate":0.6,"avgChangeRate":0.024076},{"month":10,"riseRate":0.4,"avgChangeRate":0.043974},{"month":11,"riseRate":0.5,"avgChangeRate":0.068539},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}